Sa1365 AGREEMENT BETWEEN STOMACH BIOPSY CULTURE AND STOOL NEXT-GENERATION SEQUENCING FOR DETERMINING HELICOBACTER PYLORI ANTIBIOTIC SUSCEPTIBILITY PROFILES IN A SCREENING PREDOMINANTLY HISPANIC U.S. POPULATION
Leggi →
Maggio 2024
Risultati per: Helicobacter Pylori: algoritmo terapeutico di eradicazione
Questo è quello che abbiamo trovato per te
Sa1364 TEN-VERSUS FOURTEEN-DAY VONOPRAZAN AND HIGH-DOSE AMOXICILLIN DUAL-THERAPY FOR HELICOBACTER PYLORI ERADICATION: A PROSPECTIVE, OPEN-LABELED, MULTICENTER, RANDOMIZED NONINFERIORITY STUDY
Leggi →
Maggio 2024
Sa1363 HELICOBACTER PYLORI TREATMENT, FOLLOW-UP AND OUTCOMES IN A PREDOMINANTLY HISPANIC POPULATION IN THE UNITED STATES
Leggi →
Maggio 2024
Sa1362 HELICOBACTER PYLORI DETECTION AMONG PATIENTS WITH DYSPEPSIA UNDERGOING ESOPHAGOGASTRODUODENOSCOPY ON PROTON PUMP INHIBITORS -UNPACKING THE GAP BETWEEN GUIDELINES AND CLINICAL PRACTICE.
Leggi →
Maggio 2024
Sa1377 SEVEN-DAY VONOPRAZAN-BASED TRIPLE THERAPY AS FIRST-LINE HELICOBACTER PYLORI TREATMENT IN COMPARISON WITH EXTENDED SEQUENTIAL THERAPY: A RANDOMIZED CONTROLLED TRIAL
Leggi →
Maggio 2024
653 VONOPRAZAN-BASED DUAL AND TRIPLE THERAPY VERSUS BISMUTHBASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARMED, RANDOMIZED CLINICAL TRIAL
Leggi →
Maggio 2024
572 REDUCTION OF DISPARITIES IN H. PYLORI TREATMENT AND ERADICATION FOLLOWING IMPLEMENTATION OF A MULTIDISCIPLINARY TREATMENT PROGRAM.
Leggi →
Maggio 2024
Sa1378 HELICOBACTER PYLORI ERADICATION TREATMENT REGIMEN SELECTION FOR PATIENTS WITH DECREASED RENAL FUNCTION: A SYSTEMATIC REVIEW
Leggi →
Maggio 2024
Sa1386 GENETIC VARIANTS OF HELICOBATER PYLORI THAT ARE RESISTANT TO FURAZOLIDONE AND RIFAMPICIN IN COLOMBIA
Leggi →
Maggio 2024
Sa1389 EFFICACY OF NOVEL POTASSIUM-COMPETITIVE ACID BLOCKERS, VONOPRAZAN AND FEXUPRAZAN, VERSUS CONVENTIONAL PROTON PUMP INHIBITOR-BASED TRIPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI, A RETROSPECTIVE COHORT STUDY IN A PHILIPPINE TERTIARY HOSPITAL
Leggi →
Maggio 2024
Sa1388 EFFICACY OF VONOPRAZAN-BASED TRIPLE THERAPY VERSUS PROTON PUMP INHIBITOR-BASED SEQUENTIAL AND CONCOMITANT THERAPIES AS FIRST-LINE TREATMENTS FOR HELICOBACTER PYLORI INFECTION: A PROPENSITY SCORE MATCHING ANALYSIS
Leggi →
Maggio 2024
Sa1385 TAILORED THERAPY GUIDED BY GENOTYPIC RESISTANCE BASED ON GASTRIC MUCOSAL SPECIMENS IN THE FIRST-LINE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Leggi →
Maggio 2024
Sa1384 VONOPRAZAN-AMOXICILLIN DUAL THERAPY VERSUS BISMUTH-BASED QUADRUPLE THERAPY FOR TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Leggi →
Maggio 2024
Sa1383 QUADRUPLE AND DUAL THERAPIES ARE SUPERIOR TO STANDARD CLARITHROMYCIN-BASED TRIPLE THERAPY FOR HELICOBACTER PYLORI FIRST-LINE ERADICATION THERAPY USED IN THE LATIN AMERICAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-LATAMREG).
Leggi →
Maggio 2024
Sa1382 TREATMENT OF HELICOBACTER PYLORI WITH POTASSIUM COMPETITIVE ACID BLOCKERS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Leggi →
Maggio 2024
Sa1381 EVALUATION OF IMMUNOGENICITY OF A NOVEL MULTI EPITOPEBASED VACCINE AGAINST HELICOBACTER PYLORI
Leggi →
Maggio 2024
